Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Exp Hematol. 2015 Apr 24;43(7):537–545.e11. doi: 10.1016/j.exphem.2015.03.006

Figure 2. BMS-911543 lowered and maintained white blood cell counts in murine MPN.

Figure 2

(A) The high dose group maintained white cell counts that were nearly normal and well below the vehicle-treated group for the treatment period. (B) Granulocytes, as a percentage of white blood cells, were reduced and (C) relative lymphocyte counts were elevated by high dose BMS-911543 early in the treatment period, but all groups became indistinguishable after 15 days of treatment. (D) The percentage of peripheral white cells positive for GFP increased steadily in all groups throughout the treatment period and were slightly higher in the HD group at day 31. (E, F, G) Red blood cells, hematocrit, and hemoglobin decreased steadily throughout the treatment period. (H) Platelet counts did not vary between groups. Data from ten vehicle, ten low dose, and nine high dose mice are shown. * p≤0.05 high dose vs. vehicle; § p≤0.05 low dose vs. vehicle; # p≤0.05 low dose vs. high dose. Error bars represent standard error of the mean.